Whole-body biodistribution and radiation dosimetry of 18F-GE067: a radioligand for in vivo brain amyloid imaging.
We have characterized the biodistribution and dosimetry of (18)F-3'-F-6-OH-BTA1 ((18)F-GE067), a newly developed radioligand to visualize and quantify amyloid burden, in healthy elderly human subjects.


METHODS
Six subjects (5 men and 1 woman; age range, 51-74 y) underwent dynamic whole-body PET/CT for 6 h after a bolus injection of (18)F-GE067. Source organs were delineated on PET/CT. Individual organ doses and effective doses were determined.


RESULTS
No adverse events or clinically significant changes were observed. (18)F-GE067 is excreted predominantly through the hepatobiliary system. The gallbladder, upper large intestine, and small intestine are the organs with the highest absorbed dose (average, 287, 173, and 155 microGy/MBq, respectively). The mean effective dose was 33.8 +/- 3.4 microSv/MBq, a dose comparable to that of many other (18)F-labeled radiopharmaceuticals.


CONCLUSIONS
The estimated effective dose of (18)F-GE067 for PET amyloid imaging was acceptable (class II-b defined by the World Health Organization), and relatively low variability between subjects was observed.
Nuclear Medicine, University Hospital and K.U. Leuven, Leuven, Belgium.
Michel
M
Koole
Dewi M
DM
Lewis
Christopher
C
Buckley
Natalie
N
Nelissen
Mathieu
M
Vandenbulcke
David J
DJ
Brooks
Rik
R
Vandenberghe
Koen
K
Van Laere
D000368:Aged; D016229:Amyloid beta-Peptides / Q000378:metabolism*; D052160:Benzothiazoles / Q000008:administration & dosage / Q000493:pharmacokinetics*; D001822:Body Burden; D001921:Brain / Q000000981:diagnostic imaging* / Q000378:metabolism*; D005260:Female; D006801:Humans; D008297:Male; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D009928:Organ Specificity; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals / Q000008:administration & dosage / Q000493:pharmacokinetics; D014018:Tissue Distribution; D014915:Whole-Body Counting
C542079:(18)F-GE067; D016229:Amyloid beta-Peptides; D052160:Benzothiazoles; D019275:Radiopharmaceuticals